Magnesium Threonate.

Magnesium-requiring enzymes carry out both hydroxylation steps that activate vitamin D, and higher vitamin D intake raises magnesium turnover. The relationship runs in both directions.

B6 supports magnesium entry into cells and reduces urinary loss, which is the point of a form chosen for tissue delivery.

Magnesium provides the voltage-dependent block at the NMDA receptor that keeps glutamate signalling in a normal range, and theanine modulates glutamate binding and GABA tone from a different angle.

Glycine acts at its own inhibitory receptor and at the NMDA co-agonist site, while magnesium sits in the channel pore as a voltage-dependent block. Both shape the same excitatory and inhibitory balance.

Magnesium-ATP powers the pump that holds the cell's potassium gradient, and low magnesium status makes the kidney lose potassium. Neuronal membrane potential depends on both.

Large single doses compete for intestinal divalent transport, so spacing them keeps both. At the synapse calcium drives release and magnesium restrains it.

Thiamine pyrophosphate enzymes such as transketolase and pyruvate dehydrogenase hold magnesium in the active site, and brain tissue leans heavily on both.

High zinc doses reduce magnesium balance in mineral balance work. Splitting the doses removes the overlap.

Creatine kinase works on magnesium-ATP, so magnesium is inside the reaction creatine feeds in both muscle and brain tissue. Low magnesium status caps the phosphate shuttle.

Taurine appears in the magnesium field mostly as its own carrier salt rather than as an added partner. The cited work compares two magnesium carriers head to head in a preclinical model, so it speaks to carrier chemistry and not to co-supplementation in people. Read it as mechanistic background when a formula pairs a threonate with free taurine.

Magnesium acts on NMDA receptor gating and on GABAergic tone, while melatonin acts through its own receptors on circadian timing. The two do not share a receptor, which is why they stack in evening formulas. The cited trial tested magnesium L-threonate alone, so the pairing itself has not been isolated.

Large phosphate loads bind magnesium before it reaches the absorptive surface, which is the same reaction used clinically in the other direction when magnesium salts are given as phosphate binders. Taking a high-phosphate product in the same sitting lowers what is available for uptake. Separating them in time is the straightforward answer.

Divalent metal transport in the duodenum is not perfectly selective, and large single doses of one divalent mineral reduce uptake of another taken with it. This matters at supplemental doses, not at the amounts found in food. Formulators usually split iron and magnesium across different times of day for this reason.

Phytic acid from whole grains, legumes and seeds chelates magnesium in the gut and holds it in an unabsorbable complex. Phytase cleaves the phosphate groups off phytate and releases the bound cation. The relevance is highest in plant-heavy diets and in formulas taken with a meal.

Fermentation of inulin by colonic bacteria produces short chain fatty acids that acidify the lumen, keeping magnesium in a soluble ionised state where paracellular uptake can still occur. Magnesium absorption is not confined to the small intestine, which is what makes this route relevant. The effect is on availability, not on any measured cognitive endpoint.

Boron influences how the body handles magnesium and calcium in bone mineral metabolism, and the two are commonly formulated together in bone support products. The evidence base is small and older. Read it as a nutrient interaction rather than an effect of the threonate carrier specifically.

Vitamin K-dependent carboxylation places calcium-binding groups on osteocalcin and matrix Gla protein, and the surrounding metabolism runs on magnesium-dependent enzymes. Magnesium is also a structural component of the bone mineral surface in its own right. The pairing supports normal bone mineral handling and is standard in bone formulas.

Manganese and magnesium both move as divalent cations and share partial routes of uptake, so a large dose of one blunts the other in the same sitting. Manganese doses in supplements are small, which limits how much this matters in practice. It is worth flagging in a multi-mineral where both appear at once.

Magnesium sits in the NMDA receptor channel as a voltage-dependent block, damping excitatory signalling, and it also positively modulates GABA-A receptors. Supplemental GABA acts on the same inhibitory side, though its passage across the blood brain barrier is debated. The rationale for pairing them is mechanistic, and the combination has not been isolated in a trial cited here.

Bacopa is one of the few botanicals with repeated human cognitive testing, and magnesium L-threonate is formulated toward the same use case. They work through unrelated mechanisms, so the pairing is formulation logic rather than a demonstrated interaction. Nothing here says the two together do more than either alone.

Alpha-GPC supplies choline for acetylcholine synthesis, a substrate role. Magnesium modulates glutamatergic and GABAergic signalling, a gating role. Stacking them in a cognitive formula is a design choice, and the combination itself has not been tested in the literature cited here.